Phase 2 study explores imaging approach for interstitial lung disease

Serac Healthcare has presented phase 2 data suggesting its investigational imaging agent, 99mTc-maraciclatide, may help distinguish active inflammation from fibrosis in patients with interstitial lung disease (ILD). The findings were presented at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Los Angeles and addressed a longstanding challenge in ILD management; there is […] The post Phase 2 study explores imaging approach for interstitial lung disease appeared first on Pharmafile.

Continue reading →